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Identity 
Note 
Defect in melanocyte development; one of the first 
genetic disorders for which a pedigree was presented in 
1786. 
Inheritance 
Autosomal dominant; frequency is about 2.5/105 
newborns. 
Clinics 
Phenotype and clinics 
Congenital patches of white skin and white hair, 
principally located on the scalp, forehead, chest and 
abdomen and on the limbs; several patients report 
lifelong severe constipation; a hierarchical correlation 
has been elaborated between severe or mild phenotypic 
traits and the associated KIT mutations; in a few 
patients with interstitial deletions mental retardation 
and congenital anomalies have been also described. 
Etiology: defective melanoblasts proliferation, survival 
and migration from the neural crest during 
development and defective migration of enteric-plexus 
ganglion cells from the neural crest to the gut. 
Pathology: white spotting in human piebaldism results 
from the absence of melanocytes from the 
nonpigmented patches of skin and from hairbulbs in the 
white patches of hair; occasionally, individuals lack 
ganglion cells of the intestinal enteric neural plexus, 
which like melanoblasts, are derived from the neural 
crest. 
Neoplastic risk 
An increased risk of epithelioma has been reported. 
Prognosis 
In contrast to vitiligo, piebaldism is both congenital and 
non-progressive. 
Cytogenetics 
Inborn conditions 
A few patients with interstitial deletions of 
chromosome 4q12-q21.1 have been identified; they are 
charaterized by multiple congenital anomalies, short 
stature and mental retardation. 
Genes involved and proteins 
KIT 
Location 
In 4q12. 
DNA/RNA 
Description: 21 exons. 
Protein 
Description: Transmembrane SCF/MGF receptor with 
tyrosine kinase activity; binding of ligand (SCF) 
induces receptor dimerization, autophosphorylation and 
signal transduction via molecules containing SH2- 
domains. 
Mutations 
Germinal: Loss of function mutations resulting in 
haploinsufficiency of the receptor; different kinds of 
point mutations have been identified (diagram): 
Missense substitutions (Glu583Lys; Phe584Leu; 
Ala621Thr; His650Pro; Gly664Arg; Gly791Arg; 
Arg796Gly; Val812Gly; Glu861Ala) and small 
deletions (641del2; 892 del12) in the intracellular 
tyrosine kinase domain; correlate with severe piebald 
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phenotypes, because of dominant-negative inhibition of 
the KIT receptor via formation of impaired receptor 
heterodimers between a normal and a mutant KIT 
monomer, and a 75% decrease of KIT- dependent 
signal transduction. 
Proximal frameshifts (84del1; 249del4); Trp557Term; 
and missense mutations (Cys136Arg; Ala178Thr; 
Met318Gly) associated with a mild piebald phenotype, 
the result of pure haploinsufficiency due to a 50% 
decrease of KIT-dependent signal transduction. 
Distal frameshifts: 630insA; and splice junction 
mutations (IVS1+4G-A; IVS12+1G- A), located near 
the intracellular TK domain associated with variable 
phenotypes, as the truncated polypeptides via 
incorporation into nonfunctional receptor heterodimers 
would decrease KIT-dependent signal transduction by 
50-75%, depending on their stability. 
Complete deletions of the entire KIT gene ("null" 
mutations) result in a mild- intermediate phenotype. 
PDGFRA 
Location 
4q12 
Note 
Is also deleted in patients with interstitial cytogenetic 
deletions (contiguous gene syndrome). 
SCF/MGF 
Location 
12q22 
Note 
No alteration of this gene has been so far identified in 
typical patients; at difference with the mouse system, 
where "steel" mice bearing SCF mutations show the 
"white spotting" phenotype likewise W mice bearing 
kit mutations; however, as mutations of KIT could not 
be detected in a consistent fraction of these patients, 
involvement of SCF is still an open question. 
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